General Announcement::Glenmark Specialty S.A. receives NDA Approval by the US FDA for Ryaltris Nasal Spray

Issuer & Securities

Issuer/ Manager
GLENMARK PHARMACEUTICALS LIMITED
Securities
GLENMARK PHARM US$170M2%220628 - XS1426780125 - 4G8B
Stapled Security
No

Announcement Details

Announcement Title
General Announcement
Date &Time of Broadcast
14-Jan-2022 14:41:19
Status
New
Announcement Sub Title
Glenmark Specialty S.A. receives NDA Approval by the US FDA for Ryaltris Nasal Spray
Announcement Reference
SG220114OTHRE4I6
Submitted By (Co./ Ind. Name)
Glenmark Pharmaceuticals Limited
Designation
Company Secretary & Compliance Officer
Effective Date and Time of the event
14/01/2022 00:00:00
Description (Please provide a detailed description of the event in the box below)
Glenmark Specialty S.A. (Switzerland) receives NDA Approval by the United States Food and Drug Administration (FDA) for Ryaltris Nasal Spray for the Treatment of Symptoms of Seasonal Allergic Rhinitis in Adults and Pediatric Patients 12 Years of Age and Older

Attachments

PR_SGX_14012022.pdf
Total size =1201K